Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Switzerland
/
Pharmaceuticals & Biotech
Create a narrative
SKAN Group Community
SWX:SKAN Community
1
Narratives
written by author
0
Comments
on narratives written by author
3
Fair Values set
on narratives written by author
Create a narrative
SKAN Group
Popular
Undervalued
Overvalued
Community Investing Ideas
SKAN Group
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Global Expansion And R&D Will Drive Success In 2026
Key Takeaways SKAN Group's strong order growth and substantial backlog suggest increased future revenues and visibility for the coming year. Investments in R&D, international expansion, and new AI services are positioned to enhance growth, improve margins, and increase profitability.
View narrative
CHF 86.50
FV
12.6% undervalued
intrinsic discount
20.81%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
3 days ago
author updated this narrative
Your Valuation for
SKAN
SKAN
SKAN Group
Your Fair Value
CHF
Current Price
CHF 75.60
43.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
794m
2015
2018
2021
2024
2025
2027
2030
Revenue CHF 793.9m
Earnings CHF 85.3m
Advanced
Set Fair Value